Close Menu

    Get the latest news around the globe

    Editor's Pick

    Musk launches Starlink internet service in Indonesia

    Trump to announce tariff on Steel and Aluminium Imports, Impacting Canada

    UN issues SOS warning on unprecedented rising sea levels

    Facebook X (Twitter) Instagram
    Facebook X (Twitter) LinkedIn Instagram
    Britain HeraldBritain Herald
    Subscribe
    • Home
    • World Roundup
    • Business
    • Tech World
    • Entertainment & Events
    • Curious
    • More…
      • Spotlight
      • Knowledge
      • Lifestyle
      • Awareness
      • Women World
      • Sports
      • Travel
      • Notable
      • Contact Us
    Britain HeraldBritain Herald
    Home » NHS to provide pioneering gene therapy for inherited blood disorder
    Science

    NHS to provide pioneering gene therapy for inherited blood disorder

    Clinical trials have shown that approximately 90% of patients were cured by the primary treatment with Casgevy gene therapy.
    Trainee ReporterBy Trainee ReporterAugust 8, 2024
    Facebook Twitter LinkedIn WhatsApp
    NHS to offer casgevy gene therapy
    Image Courtesy: Los Muertos Crew/Pexels | Cropped by BH

    England: A groundbreaking gene therapy, costing over £1.6 million per treatment, will soon be available to patients in England with an inherited blood disorder, making them the first in Europe to benefit from it, remarked by the National health service (NHS).

    The treatment, known as Casgevy (also referred to as exa-cel), utilises ‘molecular scissors’ to rectify a damaged gene responsible for the debilitating condition beta thalassaemia. Clinical trials have shown that approximately 90% of patients were cured by the primary treatment with Casgevy.

    Currently, individuals severely affected by the disease require frequent blood transfusions, as their red blood cells fail to carry sufficient oxygen throughout the body.

    In its final draft guidance, the National Institute for Health and Care Excellence (NICE) has stated that Casgevy will be immediately available on the NHS to treat severe beta-thalassaemia, while additional data is gathered on its cost-effectiveness.

    Helen Knight, Director of Medicines Evaluation at NICE, said that, “Although there are some uncertainties in the evidence for its long-term benefits, the committee felt exa-cel could represent a potential cure for some people with transfusion-dependent beta-thalassaemia, freeing them from the burden and risks of needing regular blood transfusions.”

    Beta thalassaemia predominantly affects individuals of Bangladeshi, Indian, and Pakistani ethnic origin in the UK. The disease leads to delayed growth, bone and hormonal issues, and impacts both life expectancy and quality.

    Initially, NICE determined that there was insufficient evidence of clinical benefit to support the cost of Casgevy, which has a list price of £1,651,000. However, the manufacturer, Vertex, agreed to a confidential discount, and approximately 460 patients over the age of 12 received the treatment through the Innovative Medicines Fund to further study its benefits.

    Casgevy gene therapy
    Image Courtesy: Artem Podrez/Pexels | Cropped by BH

    Patients with beta thalassaemia are unable to produce sufficient haemoglobin, a protein in red blood cells that carries oxygen. To rectify this, doctors remove stem cells that produce red blood cells, use the CRISPR technique (a Nobel Prize-winning method) to make precise cuts in the damaged gene, and then transfuse the corrected cells back into patients.

    In a clinical trial, 90% of the 42 individuals who received the treatment did not require a red blood cell transfusion for at least a year, while others required fewer blood transfusions.

    Yasmin Sheikh, from the stem cell charity Anthony Nolan, commented that, “We’re delighted with this historic decision to approve the UK’s first ever CRISPR-based therapy. Casgevy offers an effective cure for transfusion-dependent beta thalassaemia, a debilitating condition that was previously incurable in patients who don’t have a stem cell donor.”

    However, the charity urged NICE and Vertex to reach an arrangement that would allow casgevy to be used for sickle cell disease, another hereditary blood disorder. Although the UK medicines regulator stated that it was an effective and safe treatment for the disease last year, it is still awaiting clearance from NICE before being allowed on the NHS.

    Yasmin Sheikh added that, “This groundbreaking therapy must also be funded for people with sickle cell, where it has huge promise and is desperately needed. We hope this approval for thalassaemia demonstrates a solution is possible, and urge NICE and Vertex to work together to deliver this treatment to patients with sickle cell.”

    MOST READ| Netflix to phase out $11.99 basic plan in US

    STAR OF SECTOR 2025
    Casgevy gene therapy Casgevy o treat severe beta-thalassaemia Casgevy therapy in England Gene therapy for inherited blood disorder National health service to offer gene therapy
    Share. Facebook Twitter LinkedIn WhatsApp
    Avatar
    Trainee Reporter

    The news/article published above has been sourced, compiled, and corroborated by a Trainee Reporter at Britain Herald. If you have any queries or complaints about the published material, please get in touch with us at BritainHerald@Gmail.Com

    Newly Updated

    Texas Governor signs new Online Child Safety Bill sparking debate

    May 28, 2025

    Global heat record likely by 2029; WMO warns of rising climate risks

    May 28, 2025

    SpaceX Starship breaks up over Indian Ocean after losing control

    May 28, 2025
    STAR OF SECTOR 2025

    Business

    Volvo cars to cut 3,000 jobs in major restructuring effort

    Business May 27, 2025

    Sweden: Volvo Cars has announced strategies to cut approximately 3,000 jobs, primarily targeting office-based roles…

    Trump demands US-made iPhones; Warns of 25% tariff

    May 24, 2025

    Nike to raise prices on select items citing seasonal planning

    May 22, 2025

    CATL shares jump after Hong Kong stock market debut

    May 20, 2025
    Stay In Touch
    • Facebook
    • Twitter
    • LinkedIn
    • Instagram

    Curious

    Massive ice calving at Perito Moreno Glacier sparks concern

    May 16, 2025

    Glowing Spiral appears in night sky; Linked to SpaceX Falcon 9 Rocket

    March 25, 2025

    Once dubbed ‘Ugliest’; Blobfish triumphs as NZ ‘Fish of the Year’

    March 19, 2025

    Giant Iceberg A23a runs aground near South Georgia; Easing wildlife fears

    March 5, 2025

    Get the latest news around the globe

    Knowledge

    Clownfish shrinks to survive marine heatwaves, study reveals

    Knowledge May 22, 2025

    England: Clownfish, famously known from the film Finding Nemo, are shrinking in size to survive…

    Kashmir conflict: History of disputes, wars, and unresolved tensions

    May 9, 2025

    Snakebite survivor’s blood sparks universal antivenom discovery

    May 3, 2025

    ESA’s Biomass satellite set for launch to map forest carbon

    April 29, 2025
    18-EA-387-TryEngineeringSummerInst_BannerAd_300x250_Robot
    About Us
    About Us

    Britain Herald is a global news brand that plays a significant role in educating and informing the masses with informative content, the latest updates, and current affairs across the World.

    Operated and Managed by WellMade Network, the portal is a sister concern of GCC Business News and Emirati Times. For inquiries about Media Partnerships, Investment and other opportunities in line with our Editorial Policy, please contact us at;

    Email Us: News@BritainHerald.com
    Whatsapp: +971 5060 12456

    We Have

    Texas Governor signs new Online Child Safety Bill sparking debate

    May 28, 2025

    Global heat record likely by 2029; WMO warns of rising climate risks

    May 28, 2025

    SpaceX Starship breaks up over Indian Ocean after losing control

    May 28, 2025

    Canadian jailed for stealing iconic ‘The Roaring Lion’ photo

    May 27, 2025
    Facebook X (Twitter) LinkedIn Instagram
    • Home
    • Business
    • Tech World
    • Awareness
    • Contact Us
    Privacy & Cookies Policy | Terms & Conditions
    © 2002 BritainHerald.com, An Initiative by WellMade Network

    Type above and press Enter to search. Press Esc to cancel.